Prime Medicine, Bristol Myers Squibb
Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
Prime Medicine (NASDAQ:PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers Squibb (NYSE:BMY), which includes a $55M equity investment. Under the deal, Prime (PRME) will receive $55M upfront and the $55M investment.
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co (NYSE:BMY) to develop reagents for the next generation of ex vivo T-cell therapies.
Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb
Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is rarely straightforward.
Bristol, Prime Medicine in deal to develop T-cell therapies
Prime Medicine and Bristol Myers Squibb are collaborating on next-generation ex vivo T-cell therapies. Read more here.
Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb
Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, including up to $1.4 billion in development milestones and more than $2.1 billion in commercialization milestones, along with royalties on net sales.
Prime Medicine Inks Strategic Research Collaboration And License Agreement With Bristol Myers Squibb
Prime Medicine, Inc. (PRME) announced Monday a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY)
FierceBiotech14h
BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipeline
Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...
Strategic Focus and BMY Collaboration Bolster Prime Medicine’s Financial Outlook: Hold Rating Affirmed
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on PRME stock, giving a Hold rating today. Terence Flynn’s ...
BioSpace6h
Gene Editor Prime Medicines Signs BMS Cell Therapy Deal, Reprioritizes Pipeline
In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...
The Pharma Letter10h
Prime Medicine soars as it inks research collab with BMS
Cambridge, USA-based Prime Medicine saw its shares rocket more than 38% to $4.78 today, as it revealed a strategic research ...
Prime Medicine, Inc. (PRME) Gets a Hold from Stifel Nicolaus
Stifel Nicolaus analyst Dae Gon Ha maintained a Hold rating on Prime Medicine, Inc. (PRME – Research Report) today. The company’s ...
Prime Medicine Unveils Strategically Focused Pipeline
Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime ...
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...